Progress in Clinical Research on Novel PD-1 inhibitor Nivolumab
- VernacularTitle:程序性死亡因子-1（PD-1）抑制药新药 Nivolumab的临床研究进展
- Author:
Lingling DU
;
Jiajun XU
- Publication Type:Journal Article
- Keywords:
PD-1;
PD-L1;
PD-L2;
Tumor immunity;
Melanoma;
Non-small cell lung cancer;
Renal cell carcinoma
- From:
China Pharmacist
2015;(11):1971-1974
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To introduce a programmed death-1 (PD-1) inhibitor nivolumab used as a new antitumor agent. Methods:According to the literatures, the action mechanism of nivolumab and the clinical trial results on the main indications approved or being investigated in phase III trials were reviewed and evaluated. Results:Nivolumab could restore the antitumor activity of T cells through binding with PD-1 and consequently blocking its interaction with the key ligands of PD-L1 and PD-L2. Several completed and ongoing clinical trials showed that nivolumab used alone or combined with chemotherapy or CTLA-4 inhibitor ipilimumab exhibited better effica-cy when compared with current clinical used chemotherapy drugs in the treatment of melanoma, non-small cell lung cancer and renal cell carcinoma. Nivolumab was well tolerated during the treatment with such main grade 3-4 adverse events as immune-mediated pneu-monia, abnormal liver functions and fatigue. Conclusion:Through its anti-tumor immune response, nivolumab can improve the clinical efficacy in the treatment of various tumors including melanoma, non-small cell lung cancer and renal cell carcinoma.
